中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
23期
42-43
,共2页
替比夫定%阿德福韦酯%慢性乙型肝炎%HBeAg阳性
替比伕定%阿德福韋酯%慢性乙型肝炎%HBeAg暘性
체비부정%아덕복위지%만성을형간염%HBeAg양성
Telbivudine%Adefovir dipivoxil%Chronic hepatitis B%HBeAg positive
目的：探讨替比夫定与阿德福韦酯治疗 HBeAg 阳性慢性乙型肝炎的临床疗效。方法：2012-2013年收治HBeAg阳性慢性乙型肝炎患者90例，分为观察组及对照组，各45例，观察组应用替米夫定治疗，对照组采用阿德福韦酯治疗，连续治疗24周。结果：观察组肝功能指标改善优于对照组，比较差异有统计学意义(P＜0.05)；观察组HBeAg及HBV-DNA转阴率高，与对照组比较差异有统计学意义(P＜0.05)。结论：替比夫定治疗HBeAg阳性慢性乙型肝炎疗效优于阿德福韦酯。
目的：探討替比伕定與阿德福韋酯治療 HBeAg 暘性慢性乙型肝炎的臨床療效。方法：2012-2013年收治HBeAg暘性慢性乙型肝炎患者90例，分為觀察組及對照組，各45例，觀察組應用替米伕定治療，對照組採用阿德福韋酯治療，連續治療24週。結果：觀察組肝功能指標改善優于對照組，比較差異有統計學意義(P＜0.05)；觀察組HBeAg及HBV-DNA轉陰率高，與對照組比較差異有統計學意義(P＜0.05)。結論：替比伕定治療HBeAg暘性慢性乙型肝炎療效優于阿德福韋酯。
목적：탐토체비부정여아덕복위지치료 HBeAg 양성만성을형간염적림상료효。방법：2012-2013년수치HBeAg양성만성을형간염환자90례，분위관찰조급대조조，각45례，관찰조응용체미부정치료，대조조채용아덕복위지치료，련속치료24주。결과：관찰조간공능지표개선우우대조조，비교차이유통계학의의(P＜0.05)；관찰조HBeAg급HBV-DNA전음솔고，여대조조비교차이유통계학의의(P＜0.05)。결론：체비부정치료HBeAg양성만성을형간염료효우우아덕복위지。
To explore the clinical effect of telbivudine and adefovir dipivoxil in the treatment of HBeAg positive chronic hepatitis B.Methods:90 cases of HBeAg positive chronic hepatitis B were selected from 2012 to 2013.They were divided into the observation group and the control group with 45 cases in each.The observation group were treated with telbivudine.The control group were treated with adefovir dipivoxil.They were given continuous treatment for 24 weeks.Results:The liver function of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).The negative conversion ratios of HBeAg and HBV-DNA of patients in the observation group were high,and there was significant difference compared with the control group(P<0.05).Conclusion:Telbivudine in the treatment of HBeAg positive chronic hepatitis B has significant effect,and its effect is superior to adefovir dipivoxil.
